Feasibility of 21-day continuous infusion of epirubicin in hormone-refractory prostate cancer patients.
作者信息
Berruti Alfredo, Mosca Alessandra, Bitossi Raffaella, Gorzegno Gabriella, Guercio Stefano, Poggio Massimiliano, Tampellini Marco, Porpiglia Francesco, Ostellino Oliviero, Scarpa Roberto Mario, Dogliotti Luigi
机构信息
Gruppo Onco-Urologico Piemontese, Oncologia Medica, Departimento di Scienze Cliniche e Biologiche, Università di Torino, Azienda Ospedaliera San Luigi, Orbassano, Italy.
出版信息
Anticancer Res. 2005 Nov-Dec;25(6C):4475-9.
BACKGROUND
Epirubicin (EPX) has been found to be active in hormone-refractory prostate cancer (HRPC) patients. Prolonged EPX infusion has never been investigated in this patient subset.
PATIENTS AND METHODS
A feasibility study was conducted in which EPX was administered in 21-day continuous infusion to 15 patients with HRPC. The EPX dose was 5 mg/m2 daily for 21 consecutive days (one course). One week was allowed before starting the next course.
RESULTS
The patients received 1 to 6 courses (median 3). As a whole, the treatment was well tolerated. Nine patients did not develop any toxicity, while WHO grade 3 and 4 toxicities were recorded in 4 patients. Alopecia (WHO grade 1-2) was presented in 4 cases. Five patients attained >50% decrease in serum prostate-specific antigen (PSA).
CONCLUSION
Prolonged EPX infusion is feasible and potentially active in the treatment of HRPC patients. Our data suggest caution in administering this treatment in patients bearing rheumatologic disease.
Zotero 插件